SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alivus Life Sciences - Quaterly Results

23 Jan 2025 Evaluate
A fair growth of 12.05% in the revenue at Rs. 6418.44 millions was reported in the December 2024 quarter as compared to Rs. 5728.04 millions during year-ago period.A slim rise of 15.32% was recorded in the Net profit for the quarter ended December 2024 to Rs. 1369.60  millions  From Rs. 1187.65 millions.Operating profit for the quarter ended December 2024 rose to 2007.64 millions as compared to 1742.47 millions of corresponding quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 6418.44 5728.04 12.05 17373.39 17466.17 -0.53 22832.14 21612.20 5.64
Other Income 104.56 16.91 518.33 244.82 89.11 174.74 120.42 289.57 -58.41
PBIDT 2007.64 1742.47 15.22 5086.34 5417.12 -6.11 6862.88 6712.50 2.24
Interest 4.58 3.87 18.35 11.54 11.82 -2.37 15.46 5.47 182.63
PBDT 2003.06 1738.60 15.21 5074.80 5405.30 -6.11 6847.42 6707.03 2.09
Depreciation 151.59 131.77 15.04 446.39 389.18 14.70 534.52 420.94 26.98
PBT 1851.47 1606.83 15.23 4628.41 5016.12 -7.73 6312.90 6286.09 0.43
TAX 481.87 419.18 14.96 1190.82 1286.60 -7.44 1604.02 1616.48 -0.77
Deferred Tax 13.81 30.57 -54.82 45.19 75.00 -39.75 81.88 110.37 -25.81
PAT 1369.60 1187.65 15.32 3437.59 3729.52 -7.83 4708.88 4669.61 0.84
Equity 245.07 245.05 0.01 245.07 245.05 0.01 245.05 245.05 0.00
PBIDTM(%) 31.28 30.42 2.82 29.28 31.01 -5.60 30.06 31.06 -3.22

Alivus Life Sciences Share Price

1066.65 -6.50 (-0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×